Followers | 62 |
Posts | 10251 |
Boards Moderated | 0 |
Alias Born | 06/03/2008 |
Wednesday, March 23, 2022 5:18:05 PM
Yes, once again, a day later since the last PR!
https://www.accesswire.com/581231/DECNs-GenViroTM-COVID-19-Rapid-Kit-to-Reap-Huge-Boost-from-316-FDA-Guidance-Allowing-for-Near-Immediate-Distribution-of-Kits-Prior-to-Emergency-Waiver-Grant
DECN's GenViro!(TM) COVID-19 "Rapid" Kit to Reap Huge Boost from 3/16 FDA Guidance Allowing for Near Immediate Distribution of Kits Prior to Emergency Waiver Grant
Wednesday, March 18, 2020
Significant regulatory policy is changed so that once diagnostic validation is completed, test kits can be distributed subject only to certain labeling and testing presentations
LOS ANGELES, CA / ACCESSWIRE / March 18, 2020 /
Today, DECN announces that the company is revising strategies (and forecasts) (Ed note, oh god no, forecast raised 3 times in 3 days??) for its GenViro!™ Covid-19 test kit, a test kit that provides a coronavirus result in less than a minute, at the point of case. The company expects that it will receive a major boost from the most recent and thus far most optimistic FDA guidance for Coronavirus test kits.
On March 16, the FDA updated its COVID-19 test policy. A significant change to this policy is that once validation testing for a product has been completed, the test can be distributed to customers, entities and users, with certain labeling and a summary of test results provided on the company website (and/or the package). GenViro!™ has been validated at the company's R&D center in Daegu, Korea for the H5N1 virus and most recently the methodologically similar corona virus. The new FDA policy is available to read at: https://www.fda.gov/media/135659/download
Keith Berman, CEO of DECN commented, "In the last 24 hours we have witnessed a sea change in how the FDA is processing applications for Covid-19 diagnostic kits, and in doing so is allowing some of these kit products to be sold or provided once test validation is provided. While the company will still need to provide ample data and a full discussion of its unique technology in the coming days, the new FDA policy will provide a channel that will allow the company to manufacture test kits and put these kits into distribution almost immediately. This same unperturbed policy will also allow us to quickly add our second GenViroTM product designed for hospitals and for clinics and commercial labs desirous of a confirmatory method for those who test positive for coronavirus."
Mr. Berman concluded, "I have been in and around the in-vitro diagnostics business for over 40 years, and never before in all of that time, have I witnessed a policy like this. This latest guidance from the FDA shaves months from our product development process, and we all shall reap these benefits. Tomorrow we will discuss our new plans going forward now that we will shortly be a two product coronavirus diagnostics company."
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM